Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb Plans Major Expansion Of R&D Facilities

Premium

PRINCETON, N.J.--Bristol-Myers Squibb is buying a 433-acre research and office park in Hopewell Township, N.J., to house a major expansion of the pharmaceutical company's R&D efforts. The expansion will add approximately 2,000 staff, an increase of 50 percent, over the next five years, the company said. Its pharmaceutical R&D spending this year is expected to be $1.3 billion.

Among other things, the expansion is aimed at creating more drugs in-house and relying less on licensing products developed by other companies. Bristol-Myers Squibb is currently involved in about 30 research alliances that provide expertise in such areas as bioinformatics, genomics, combinatorial chemistry, high-throughput screening, and molecular modeling.

The new facility will support the goal of Peter Ringrose, the new president of the company's Pharmaceutical Research Institute, to discover more compounds, speed drug development, expand into new disease areas, and bring new leadership to the research group.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.